Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus

Novo Nordisk A/S526 enrolled

Overview

This study is conducted in Asia. The aim of this observational study is to evaluate subjects' treatment satisfaction and to evaluate subjects' preference of pen device and the incidence of clinical technical complains while using NovoPen® 4 under normal clinical practice conditions.

Study Type

OBSERVATIONAL

Enrollment

526

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Delivery Systems

Interventions

NovoPen® 4DEVICE

Insulin administration by means of a NovoPen® 4 pen device

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Any subject with Type 1 or Type 2 diabetes and accepting to use NovoPen® 4. The selection will be at the discretion of the individual physician. * A study specific signed informed consent must be signed by each subject before any study-related activities or information is collected, if required by local regulations Exclusion Criteria: * Subjects who are unlikely to comply with the protocol, e.g., unwillingness to cooperate, inability to return for the final visit * Subjects with known or suspected allergy to any insulin or any of its excipients

Locations (1)

Novo Nordisk Investigational Site

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

The change in subjects' satisfaction with insulin therapy, measured by change from visit 1 to visit 2 in subject treatment satisfaction scores on the DTSQ (Diabetes Treatment Satisfaction Questionnaire)

Time frame: 3 months

Secondary Outcomes

Subjects' device preference

Time frame: 3 months

Subjects' NovoPen® 4 evaluation

Time frame: 3 months

Number of clinical technical complaints

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.